Corporate and business development (consultant) @ TopiVert Pharma Ltd
BSc Hons @
University of Leeds
A Senior Executive with more than 15 years international experience in corporate and business development. Nick has been a critical player in the completion of several major M&A, licensing, new business ventures and fundraising transactions in the pharmaceutical and healthcare sectors. Visionary leadership and a deep understanding of the pharmaceutical industry and the capital markets is supported
A Senior Executive with more than 15 years international experience in corporate and business development. Nick has been a critical player in the completion of several major M&A, licensing, new business ventures and fundraising transactions in the pharmaceutical and healthcare sectors. Visionary leadership and a deep understanding of the pharmaceutical industry and the capital markets is supported by exceptional strategic, analytical and communications skills.
He is currently undertaking consulting projects through USUS Consulting while seeking a leadership role in growth company.
Specialties: deal search, selection, evaluation, negotiation, execution across business development, licensing and M&A, together with commercial and equity analysis expertise, corporate strategy & IR
Corporate and business development consultancy (an interim step) @ Various business development and corporate development projects for clients including: (i) the acquisition for Abzena PLC of PacificGMP, a privately held contract biopharmaceutical development and manufacturing company (CDMO) based in San Diego, CA, USA (ii) 12 month corporate development interim role for Retroscreen plc with a £4 million all share acquisition of Activiomics Ltd a private UK proteomics company, a successful £33.6 million fundraising and a corporate rebranding in line with the company's broader business strategy.(iii) a range of corporate development projects including due diligence, valuation and transaction support. From November 2013 to Present (2 years 2 months) London, United KingdomDirector of Business Development & Licensing, Emerging Markets @ Interim role focused on business development and licensing activities to leverage in-house respiratory products and technologies in key emerging markets including China From November 2012 to September 2013 (11 months) Director of Corporate Development, Emerging Markets @ Lead role in establishing a Chinese JV company called Tianjin Kinnovata Pharmaceutical Company Limited in China with two partners: Tianjin KingYork Pharmaceuticals Tianjin KingYork Group Company Limited ("KingYork"), a leading Chinese pharmaceutical company and specialist manufacturer of corticosteroid based products, and Zendex Bio Strategy Inc a private equity investor based in Hong Kong.
Kinnovata will develop, manufacture and commercialise respiratory products for the rapidly growing domestic Chinese and other regional markets in Asia. From January 2011 to November 2012 (1 year 11 months) Director of Business Development @ Primarily focused on growing global brands Durex and Scholl through international product acquisitions until acquisition by Reckitt Benckiser From April 2010 to January 2011 (10 months) Founder @ Freelance business development consulting for a number of international clients From April 2009 to March 2010 (1 year) Director of Corporate Affairs (Corporate Development) @ A broad corporate role, reporting into CEO, responsible for Corporate Development including M&A, strategy, IR/PR, fundraising and managing the capital markets From November 2003 to April 2009 (5 years 6 months) Equity Analyst @ A prominent and respected analyst in the leading biotech banking franchise in the EU at the time.
Lead analyst on eight Life Science companies in the EU, generating significant secondary commission as the authoritative voice on several high profile stocks From October 2000 to July 2003 (2 years 10 months) Consultant @ Management Consultant in the Life Sciences Team within the Technology Consulting Practice. Primary focus was on due diligence for IPOs and M&A, product forecasting including 9 months secondment tor GSK, and the strategic implications of biotechnology on existing industries. From 1997 to 2000 (3 years)
PhD, Biochemistry @ University of Cambridge From 1991 to 1996 BSc Hons, Biochemistry with Molecular Biology @ University of Leeds From 1988 to 1990 Nick Staples is skilled in: Mergers, Business Strategy, Biotechnology, New Business Development, Corporate Development, Equities, Pharmaceuticals, Emerging Markets, Healthcare, Life Sciences, Financial Modeling, Strategic Planning, Business Planning, Due Diligence, Negotiation
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension